Travere Therapeutics Surges After Swinging to Q3 Profit and Crushing Analyst Estimates

Travere Therapeutics shares jumped 15% after reporting a strong Q3 profit of $25.7M, driven by surging FILSPARI sales and better-than-expected earnings. Citi raised its price target to $48, citing optimism for FDA approval in early 2026.